Alligator Bioscience (Q1 2026 Review): Pragmatic Path to Phase III - Redeye

Redeye returns with an update following Alligator Bioscience’s Q1 earnings release. The report was uneventful, as expected for a pre-revenue biotech company. Costs continued trending downwards in line with our expectations. We adjust our financing assumptions while lowering our WACC. Our fair value range of SEK0-1.7, with a base case of SEK0.3, is reiterated.

Länk till analysen i sin helhet: https://www.redeye.se/research/1164649/alligator-bioscience-q1-2026-review-pragmatic-path-to-phase-iii?utm_source=finwire&utm_medium=RSS